ACCESS Newswire

NOSIBLE Raises $1 Million Pre-Seed, Welcomes Industry Veteran Axel Hörger

Share

Funding led by Atlantica Ventures supports the launch of nosible.ai, an arena of hyperspecialized AI agents that automate time-intensive tasks in asset management.

SAN FRANCISCO, CA AND NEW YORK, NY / ACCESS Newswire / March 26, 2025 / NOSIBLE, an upcoming AI startup, today announces it has secured $1 million in pre-seed funding led by Atlantica Ventures, alongside additional strategic investments from existing customers. The funding will support NOSIBLE in launching its growth marketing efforts, scaling its sales operations, and accelerating its go-to-market strategy.

Founded by Stuart Reid, a computer scientist and quantitative analyst with over a decade of experience building large-scale AI systems, NOSIBLE is on a mission to become the leading AI provider to asset managers. After working with existing technology for many years Stuart and Matthew Dicks, a founding engineer at NOSIBLE, made a remarkable discovery - a novel solution to one of AI's most challenging puzzles, approximate nearest neighbors.

NOSIBLE's solution is uniquely optimized for disk, supports native pre-filtering, compression, streaming, bulk querying, and even real-time hyperparameter tuning. These characteristics combine to create a solution that is 100x cheaper than the current state-of-the-art in large-scale search. Recognizing search as a scaling law, NOSIBLE's innovation unlocks smarter AI agents because they search 100x more.

"Our discovery changes the AI equation," said Stuart Reid, Founder and CEO of NOSIBLE. "Our index operates at 1/100th the cost of current methods and uniquely supports real-time hyperparameter tuning, allowing it to dynamically adapt to more complex searches - similar to how OpenAI pioneered the use of test-time compute."

Speaking on their investment, Ik Kanu, Founding Partner at Atlantica Ventures adds, "We invested in NOSIBLE because we saw a small, focused team that was deeply knowledgeable in quantitative finance, ML, and computer science, building their own infrastructure to power a low-cost, agentic platform with intelligent workflows. This unique blend of finance and tech expertise allows NOSIBLE to deliver highly specialized value for small to large asset managers with impressive capital efficiency - it's exactly the kind of focused innovation we look for."

Joining NOSIBLE at this critical stage is industry veteran Axel Hörger, who comes on board as Advisor. Hörger brings nearly three decades of experience in executive leadership roles at leading financial institutions, including Lombard International, UBS, and Goldman Sachs. His extensive network and deep expertise in capital markets and next-generation digitalization will be pivotal in accelerating NOSIBLE's influence.

"NOSIBLE's innovation unlocks exciting new opportunities by enabling AI agents to perform more searches, enhancing the depth and accuracy of their results", explained Hörger. "The team has developed a technology with the potential to reshape AI analytics entirely, and I'm thrilled to join NOSIBLE at this important stage and leverage my experience to help drive the next phase of growth."

Alongside the new funding, the company has released nosible.ai - a competitive arena featuring hyperspecialized AI agents designed to deliver targeted and accurate responses to users' questions. Unlike generalized "God models" popularized by large AI labs, each nosible.ai agent focuses exclusively on performing one task exceptionally well, improving continuously through extensive search interactions.

NOSIBLE's core thesis is straightforward: the more its AI agents search, the smarter they become. For instance, its research agent can quickly analyze data in minutes, which traditionally requires 20 hours. By drastically reducing the cost of web-scale search, NOSIBLE believes its agents will deliver significantly deeper insights.

Reid concludes, "nosible.ai agents empower asset managers to do the impossible. With lower search costs, our agents can deliver unprecedented analytical depth."

NOSIBLE is redefining expectations for AI agents and setting new standards for web-scale search, paving the way for future innovations.

- ENDS-

For additional information on NOSIBLE or interview requests, please contact Timileyin Omilana at timileyin@wimbart.com

About NOSIBLE

Founded in 2020, NOSIBLE is an emerging AI startup, offering two core products: a powerful search engine API that provides businesses with real-time and historical data insights, and nosible.ai, a consumer-facing platform featuring hyperspecialized AI agents designed to streamline asset management tasks.

SOURCE: NOSIBLE INC



View the original press release on ACCESS Newswire

NOSIBLE INC

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

SK tes Launches New Circular IT Facility in Shannon, Expanding Ireland’s Role in Global Sustainable Tech Services24.4.2025 09:30:00 CEST | Press release

SHANNON, IE / ACCESS Newswire / April 24, 2025 / SK tes, a global leader in sustainable IT asset disposition (ITAD) and technology lifecycle services, has announced plans to open a new 36,000 square foot purpose-built facility in Shannon, marking a major vote of confidence in Ireland's thriving data and technology sector. The new facility will deliver comprehensive ITAD, data center decommissioning, and technology lifecycle management services to some of Ireland's largest enterprises, including hyperscale data center operators, while supporting national sustainability and circular economy goals. It will also create over 25 skilled jobs in one of the country's fastest-growing tech regions. "Ireland is at the forefront of Europe's digital economy, and our investment in Shannon reinforces our commitment to helping Irish companies manage technology securely, sustainably, and at scale," said Eric Ingebretsen, Chief Commercial Officer at SK tes. "This facility will allow us to meet the uniqu

Sauce Labs Launches Industry-First Enterprise Scale iOS 18 Testing on Sauce Labs Virtual Device Cloud, Boosting Test Speeds up to 40%24.4.2025 08:00:00 CEST | Press release

Leading test automation platform, powering development for over 300,000 active users and having executed more than 8 billion tests, enables developers and QA teams to ensure app quality on Apple's latest OS with unprecedented performance and scale. SAN FRANCISCO, CA / ACCESS Newswire / April 24, 2025 / Sauce Labs Inc., the leading platform for continuous quality, trusted by dev teams around the world to deliver apps users love, today announced the general availability of iOS 18 testing on its Virtual Device Cloud (VDC). Leveraging its new, high-performance Apple Silicon cloud infrastructure, Sauce Labs offers the market's most scalable enterprise-ready solution for automated mobile app and web testing on iOS 17.5, iOS 18, and beyond, enabling teams to execute tests up to 40% faster compared to previous versions. This launch addresses the critical need for timely testing support driven by Apple's transition to its proprietary Apple Silicon architecture and the rapid adoption rate of new

Introducing NUGEN(R) HLD-CD by Arxada: A Game-Changer in Healthcare Disinfection24.4.2025 07:00:00 CEST | Press release

Delivering Effective Germ Control in Five Minutes BASEL, CH / ACCESS Newswire / April 24, 2025 / Arxada, a global leader in specialty chemicals and innovative solutions, announces the launch of NUGEN® HLD-CD, a revolutionary healthcare disinfectant. This game-changing solution disinfects medical devices in just five minutes, ensuring that even the most resilient microorganisms, which can withstand harsh conditions, are destroyed.* NUGEN® HLD-CD is designed to meet the rigorous demands of healthcare environments. Its broad efficacy spectrum and short contact times make it suitable for all critical areas, including operating rooms, isolation areas, and intensive care units where speed and safety are essential. "We are excited to introduce NUGEN® HLD-CD to the healthcare market," said Uwe Holland, Head of Professional Hygiene EMEA at Arxada. "This solution is a game-changer in disinfection technology for healthcare facilities, providing professionals with a powerful means to improve patie

TCL Introduces the TCL T6C-UK Fire TV Series with QLED 4K, HDR PRO, and Freely23.4.2025 07:30:00 CEST | Press release

LONDON, UNITED KINGDOM / ACCESS Newswire / April 23, 2025 / TCL, the leading consumer electronics brand and the world's second-largest TV brand as well as an official sponsor of the Olympic Games, is proud to announce the launch of its highly anticipated T6C-UK TV series. The new range offers screen sizes from 43" to 85", ensuring there is a perfect option for every home. Featuring QLED technology, 4K resolution, and an intuitive Fire TV experience, the T6C-UK series offers exceptional picture quality, seamless content access, and smart functionality. The TCL T6C-UK series comes Freely-enabled, offering a seamless way to enjoy live and on-demand TV - all in one place and completely free. With Freely built-in, users can access their favourite streaming apps at the click of a button, eliminating the need to switch between platforms. From major channels to must-watch shows, everything is easily accessible from a single, intuitive home screen. Powered by Fire TV, the T6C-UK series also fea

BioNxt Solutions Prepares for Human Bioequivalence Study For MS23.4.2025 03:05:00 CEST | Press release

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment. BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish. T

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye